The use of estramustine phosphate in the modern management of advanced prostate cancer

Combining Docetaxel With Estramustine: Back to the Future?

(2009) Stéphane Oudard et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial

(2008) Orazio Caffo et al.   BJU INTERNATIONAL

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

(2008) C. Ay et al.   BLOOD

Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer

(2008) Jean-Pascal Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Tissue Factor–Bearing Microparticles and Cancer

(2008) Jeffrey Zwicker   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone

(2008) Orazio Caffo et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS